SURF - Surface Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Surface Oncology, Inc.

50 Hampshire Street
8th Floor
Cambridge, MA 02139
United States

Full Time Employees76

Key Executives

NameTitlePayExercisedYear Born
Mr. Daniel S. LynchExec. Chairman52.54kN/A1958
Mr. J. Jeffrey GoaterCEO, Pres & Director658.62kN/A1975
Dr. Vito J. PalombellaChief Scientific Officer505.02kN/A1963
Dr. Robert W. RossChief Medical Officer495.01kN/A1974
Ms. Jessica FeesSr. VP of Fin. & Bus. Operations and TreasurerN/AN/A1972
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Surface Oncology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.